ENTA Stock Forecast: Enanta Pharmaceuticals, Inc. Price Predictions for 2026-2027
The 6 Wall Street analysts covering Enanta Pharmaceuticals, Inc. hold a median 12-month price target of $20 — +162.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 79 of 100 as at 21 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Enanta Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (88): The business earns solid, repeatable profits on what it owns.
Revisions (25): Analysts have, on balance, been cutting their forecasts.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
ENTA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ENTA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +162.8% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 20 Nov 2026 | JP Morgan | Maintains | Overweight | $19 → $17 |
| 23 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $20 |
| 23 June 2026 | HC Wainwright & Co. | Reiterates | Buy | $20 |
| 10 Feb 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 9 Jan 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Nov 2025 | JP Morgan | Initiates | Overweight | — |
| 1 Oct 2025 | Jefferies | Upgrade | Buy | — |
| 30 Sept 2025 | WestPark Capital | Maintains | Buy | — |
| 15 Sept 2025 | Evercore ISI Group | Maintains | Outperform | — |
| 2 Sept 2025 | WestPark Capital | Initiates | Buy | — |
| 12 Aug 2025 | JMP Securities | Maintains | Market Outperform | — |
| 28 July 2025 | HC Wainwright & Co. | Assumes | Buy | $20 |
| 3 June 2025 | JMP Securities | Maintains | Market Outperform | — |
| 14 May 2025 | JMP Securities | Maintains | Market Outperform | — |
| 11 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Feb 2025 | JMP Securities | Reiterates | Market Outperform | — |
| 24 Dec 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 26 Nov 2024 | Baird | Maintains | Outperform | — |
| 26 Nov 2024 | JMP Securities | Reiterates | Market Outperform | — |
| 10 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ENTA.
This page is one stock. Monday covers all of them.
ENTA appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
ENTA vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Enanta Pharmaceuticals, Inc. returned −37.3% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
ENTA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 3.5×
- Price / book
- 2.8×
- EV / EBITDA
- —
Cheaper than 30% of US stocks
Cheaper than 33% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- −99.0%
- Net margin
- —
Higher than 14% of US stocks
- Return on equity
- −94.2%
- Return on assets
- −14.0%
- Dividend yield
- —
Higher than 14% of US stocks
Higher than 23% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Enanta Pharmaceuticals, Inc. has a market value of $232.4M and an enterprise value of $215.8M.
Revenue in the twelve months to 30 June 2026: $65.3M. The latest quarter shrank 21.6% year on year.
Net income over the same four quarters: −$63.2M, a −96.9% net margin.
Diluted earnings per share, trailing twelve months: −$2.41.
Free cash flow in the twelve months to 30 June 2026: −$36.9M.
Enanta Pharmaceuticals, Inc. employs 74 people — $882K of revenue per employee.
Data provided by Twelve Data
ENTA and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at ENTA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Enanta Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about ENTA
What is the ENTA stock price forecast for 2026-2027?
The 6 Wall Street analysts covering Enanta Pharmaceuticals, Inc. have a median 12-month price target of $20, with estimates ranging from $17 to $32. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ENTA stock a buy right now?
Of the 6 analysts covering Enanta Pharmaceuticals, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Enanta Pharmaceuticals, Inc. 79 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ENTA?
As at 21 Nov 2026, Enanta Pharmaceuticals, Inc. ranks 79 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (88 of 100).
Will ENTA stock go up?
No one can know that. What the data says: the median 12-month target from 6 analysts implies +162.8% from the last close, and Ticker Nerd's factor model ranks Enanta Pharmaceuticals, Inc. 79 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ENTA stock forecast for 2030?
No analyst covering Enanta Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ENTA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $17 to $32 over the next 12 months.
How has ENTA stock performed over the past year?
Enanta Pharmaceuticals, Inc. returned -37.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Enanta Pharmaceuticals, Inc. do?
Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on discovering and developing small molecule therapies for viral infections and immunological diseases. Its current portfolio centers on virology and immunology, with programs spanning respiratory syncytial virus, hepatitis B, and other infectious or inflammatory conditions.
About Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on discovering and developing small molecule therapies for viral infections and immunological diseases. Its current portfolio centers on virology and immunology, with programs spanning respiratory syncytial virus, hepatitis B, and other infectious or inflammatory conditions. Enanta also generates value through its collaboration with AbbVie, including royalty interests tied to glecaprevir, a component of a hepatitis C treatment regimen marketed by AbbVie. The company’s work combines medicinal chemistry, drug discovery, and clinical development to advance oral therapies aimed at areas with significant unmet medical need. Headquartered in Watertown, Massachusetts, Enanta Pharmaceuticals plays a specialized role in the biotechnology market by supporting both partnered products and its own pipeline of investigational medicines.
CEO Dr. Jay R. Luly Ph.D. · 74 employees · United States · https://www.enanta.com